StockData
Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc. (FLGT) income statement

FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3044% below fair value
$25.13+0.92 (+3.80%)

Close on Nov 18, 2026Market cap $691.46MP/E –Yield –

Fulgent Genetics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
35.6%
Operating margin
-37.7%
Net margin
-26.0%
Return on equity, FY2025
-5.4%

Financial strength

Current ratio
6.34
Debt to equity
0.00
Debt to assets
0.1%
Cash to current liabilities
36.7%

Valuation

P/E ratio
–
Price to sales
2.13
Price to book
0.69
Dividend yield
–

See a number that looks wrong?